Skip to main content
PSTV
NASDAQ Life Sciences

加州蓝盾保险公司涵盖Plus Therapeutics的CNSide®检测，扩大到8,100万人

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$5.955
Mkt Cap
$41.104M
52W Low
$2.9
52W High
$23.425
Market data snapshot near publication time

summarizeSummary

与加州蓝盾保险公司的这一协议显著扩大了Plus Therapeutics的CNSide®脑脊液检测的市场准入，增加了600万名受益人，总数达到8,100万。这一商业里程碑对于Plus Therapeutics尤为重要，后者最近在其最后一次10-K中报告了大量净亏损和对其持续经营能力的担忧。预计扩大的覆盖范围将通过减少报销障碍来加速CNSide在肿瘤中心的采用，从而直接影响产品的商业动力和潜在的收入增长。交易者将密切关注CNSide的采用率以及公司实现2026年1.5亿名受益人的目标进展情况，这些是财务改善的关键指标。

在该公告发布时，PSTV的交易价格为$5.95，交易所为NASDAQ，所属行业为Life Sciences，市值约为$4110.4万。 52周交易区间为$2.90至$23.43。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed PSTV - Latest Insights

PSTV
Apr 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Blue Shield of California Covers Plus Therapeutics' CNSide® Assay, Expanding Access to 81 Million Lives
Sentiment: Positive
View Wiseek Article
PSTV
Apr 21, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Plus Therapeutics Regains Nasdaq Compliance, Resolving Delisting Risk
Sentiment: Positive
View Wiseek Article
PSTV
Apr 09, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Plus Therapeutics Appoints Dr. Eric J. Daniels as Chief Development Officer
Sentiment: Positive
View Wiseek Article
PSTV
Apr 08, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Plus Therapeutics Secures FDA Orphan Drug Designation for REYOBIQ in Pediatric Malignant Gliomas
Sentiment: Positive
View Wiseek Article
PSTV
Apr 02, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Plus Therapeutics Executes 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing
Sentiment: Negative
View Wiseek Article
PSTV
Apr 02, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Highmark Covers Plus Therapeutics' CNSide Assay, Expanding Reimbursement to 75 Million Lives
Sentiment: Positive
View Wiseek Article
PSTV
Mar 31, 2026, 4:20 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on Major Equity Plan Expansion and Evergreen Provision
Sentiment: Neutral
View Wiseek Article
PSTV
Mar 31, 2026, 7:35 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Plus Therapeutics Announces Reverse Stock Split to Meet Nasdaq Listing Requirements
Sentiment: Negative
View Wiseek Article
PSTV
Mar 19, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
CNSide® Diagnostic May Cut Leptomeningeal Metastases Healthcare Costs by 40%, Boosting Commercialization Prospects
Sentiment: Positive
View Wiseek Article
PSTV
Mar 12, 2026, 4:29 PM EDT
Filing Type: 10-K
Importance Score:
9
Annual Report Reveals Going Concern, Nasdaq Delisting Risk, and Heavy Dilution from Recent Financings
Sentiment: Negative
View Wiseek Article